Conditions: Esophageal Cancer
Keywords: Esophageal Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 40
Healthy volunteers: no

Brief summary:
Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001

Detailed description:
32 patients with esophageal or gastroesophageal junction cancer will receive Radiation:50.4 Gy at 180cGy fraction/day for 28 treatments and Paclitaxel Poliglumex (PPX) and Cisplatin weekly times 6 followed by surgery.

Arms:
arm 1: PPX 50mg/m2 wk and cisplatin 25mg/m2 wk for 6 weeks with 50.4 GY concurrent radiation

Interventions: intervention 1: PPX with cisplatin and radiation
Intervention descriptions: intervention 1: weekly IV treatment of Paclitaxel Poliglumex and Cisplatin for 6 weeks

Protocol document: